Viking Therapeutics Advances Oral Obesity Drug into Phase 3 Trials

  • Viking Therapeutics initiates Phase 3 trials for oral VK2735, a dual GLP-1/GIP agonist, targeting obesity with and without type 2 diabetes.
  • SUNRISE-1 and SUNRISE-2 studies will enroll 560 adults each, evaluating once-daily oral VK2735 for 68 weeks.
  • Primary endpoint is percent change in body weight from baseline compared to placebo.
  • Viking also conducting Phase 3 trials for subcutaneous VK2735 and a maintenance dosing trial for oral VK2735.

Viking Therapeutics is advancing its oral obesity drug VK2735 into Phase 3 trials, competing in a crowded market dominated by GLP-1 and dual GLP-1/GIP agonists like tirzepatide. The company aims to differentiate itself with an oral formulation, potentially offering greater convenience and adherence for patients. Success in these trials could position Viking as a key player in the obesity treatment space, alongside established competitors like Novo Nordisk and Eli Lilly.

Clinical Efficacy
Whether oral VK2735 can replicate Phase 2 results showing up to 12.2% body weight reduction in Phase 3 trials.
Market Differentiation
How Viking positions oral VK2735 against existing GLP-1/GIP agonists like tirzepatide in the obesity treatment landscape.
Regulatory Pathway
The pace at which Viking can secure approvals for both oral and subcutaneous formulations of VK2735.